Valproic acid could help in the fight against COVID-19: A case–control study
Patients with VPA within the therapeutic range had a reduction of SARS-Cov-2 infection incidence greater than 75%. There is a downward trend in the risk of COVID-19 admission by SARS-CoV-2 in patients on VPA therapy. These findings warrant further investigation.
Authors
- Esperanza Merino (ORCID: https://orcid.org/0000-0003-3854-4874)
- C Díaz-Marín (ORCID: https://orcid.org/0000-0002-4495-5736)
- Pablo Chico-Sánchez (ORCID: https://orcid.org/0000-0003-2809-8751)
- José Manuel Ramos (ORCID: https://orcid.org/0000-0002-6501-9867)
- Sergio Reus (ORCID: https://orcid.org/0000-0002-3320-9754)
- José Sánchez–Payá (ORCID: https://orcid.org/0000-0003-4847-0565)
- Rosario Sánchez‐Martínez (ORCID: https://orcid.org/0000-0003-0408-3029)
- Joaquín Portilla (ORCID: https://orcid.org/0000-0002-3676-9511)
- Óscar Moreno (ORCID: https://orcid.org/0000-0002-8670-6404)
- Vicente Boix (ORCID: https://orcid.org/0000-0002-7015-3948)
- Juan Carlos Rodrı́guez (ORCID: https://orcid.org/0000-0001-8007-5739)
Institutions
- Universitat de Miguel Hernández d'Elx (ES)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) (ES)
Publication Details
- Journal
- Neurología (English Edition)
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1016/j.nrleng.2023.12.009
- Citations
- 2
- Primary Topic
- Pharmacological Effects and Toxicity Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.11